Endoscopic Ultrasound-Guided Gallbladder Drainage
Acute cholecystitis affects ∼200,000 individuals annually in the United States, with laparoscopic cholecystectomy as the gold standard treatment. However, in high-risk surgical candidates, alternative drainage methods are necessary. Percutaneous transhepatic gallbladder drainage (PT-GBD) has traditionally served as the primary alternative intervention, offering rapid decompression, but is limited by a negative impact on the patient's quality of life, the risk of long-term or even permanent tube placement, adverse events, and high recurrence rates. Endoscopic approaches, such as endoscopic transpapillary gallbladder drainage (ET-GBD) and, more recently, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), have emerged as viable alternatives to PT-GBD. EUS-GBD, first introduced in 2007, offers technical and clinical outcomes comparable to PT-GBD with fewer adverse events, shorter hospital stays, and lower rates of recurrence. The introduction of lumen-apposing metal stents (LAMS) has revolutionized EUS-GBD, simplifying deployment and enabling subsequent internal gallbladder access, which allows additional interventions such as cholecystoscopy and stone removal. EUS-GBD is now supported by international guidelines, and 1 device has achieved FDA approval for the management of acute cholecystitis in nonsurgical candidates. Proper patient selection is essential, guided by multidisciplinary evaluation, with EUS-GBD contraindicated in specific scenarios such as gallbladder perforation, coagulopathy, and large-volume ascites. Technical considerations include choice of access site (transgastric versus transduodenal), stent type, and procedural route [direct (freehand) or wire-guided]. Postprocedural care and stent management remain variable and nonstandardized. Emerging data suggest that interval cholecystectomy can still be performed safely after EUS-GBD. As adoption of EUS-GBD with LAMS expands, structured training and standardization of practice are crucial to optimizing outcomes.
Authors
- Rahul Pannala (ORCID: https://orcid.org/0000-0001-8189-0655)
- Andrés Gelrud (ORCID: https://orcid.org/0000-0002-5112-4076)
- Shayan Irani (ORCID: https://orcid.org/0000-0002-5490-692X)
- Dmitriy O. Khodorskiy
- Gregory Lam
- Neil Bhogal
- Andrew Canakis (ORCID: https://orcid.org/0000-0002-6646-6693)
- Gurneet Bedi
- Shifa Umar
- Amy Tyberg (ORCID: https://orcid.org/0000-0001-5760-8170)
- Ricardo Marrero Torres
- Jessica Widmer
- Kenechukwu Chudy‐Onwugaje
- Thomas Tielleman
- Vladimir Kushnir
- Mankanwal S. Sachdev
- Moamen Gabr
- Neil Sharma
- Rafael Ching Companioni
- Douglas G. Adler
- Todd H. Baron
- Stuart Amateau
- Eun Ji Shin
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Minnesota (US)
- Peninsula Regional Medical Center (US)
- Johns Hopkins University (US)
- Baylor College of Medicine (US)
- Washington University in St. Louis (US)
- Kingsborough Community College (US)
- Porter Adventist Hospital (US)
- Johns Hopkins Medicine (US)
- Franciscan Health (US)
- Banner Health (US)
- WinnMed (US)
- Troy Gastroenterology (US)
- St. Anthony’s Hospital (US)
- Lagos State Health Service Commission (NG)
- Hackensack Meridian Health (US)
- Tri Center (US)
- Ohio Gastroenterology and Liver Institute (US)
- Gulf Coast State College (US)
- University of Cincinnati (US)
- The University of Texas Southwestern Medical Center (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2026-07-23
- DOI
- https://doi.org/10.1097/mcg.0000000000002409
- Primary Topic
- Gallbladder and Bile Duct Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00